McKesson (MCK) Tops Q1 EPS by 2c, Revenues Miss; Offers FY19 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
McKesson (MCK) PT Lowered to $134 at Baird; Remains Sidelined
July 27, 2018 7:15 AM EDTBaird lowered its price target on McKesson (NYSE: MCK) to $134.00 (from $141.00) while maintaining a Neutral rating. MCK claims in-line performance across all three segments. However, YY EBIT facts: U.S. +2% on easy/transitory prior-year comparison, EU -12%, Med-Surg flat, Other -8%. Three of... More
Pharma's middlemen see shares suffer as challenges grow
July 25, 2018 12:04 PM EDTBy Lewis Krauskopf
NEW YORK (Reuters) - Uncertainty over potential actions to reduce prescription drug costs and competitive threats have taken a toll this year on shares of companies in the U.S. pharmaceutical supply chain. They get their chance to change investor sentiment with quarterly earnings reports in the coming days.
Prescription drug wholesalers, drug store chains and pharmacy benefit managers generally have seen their stock prices tumble this year, even as the overall S&P 500 healthcare sector has gained 6 percent.
Six S&P 500 stocks - CVS Health Corp (NYSE:... More
